Cero Therapeutics Holdings Stock Cash And Equivalents
| CEROW Stock | 0.01 0.01 33.33% |
CERo Therapeutics Holdings fundamentals help investors to digest information that contributes to CERo Therapeutics' financial success or failures. It also enables traders to predict the movement of CERo Stock. The fundamental analysis module provides a way to measure CERo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CERo Therapeutics stock.
CERo |
CERo Therapeutics Holdings Company Cash And Equivalents Analysis
CERo Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
CERo Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for CERo Therapeutics is extremely important. It helps to project a fair market value of CERo Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since CERo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CERo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CERo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, CERo Therapeutics Holdings has 0.0 in Cash And Equivalents. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.
CERo Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CERo Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CERo Therapeutics could also be used in its relative valuation, which is a method of valuing CERo Therapeutics by comparing valuation metrics of similar companies.CERo Therapeutics is currently under evaluation in cash and equivalents category among its peers.
CERo Fundamentals
| Return On Asset | -0.45 | ||||
| Number Of Shares Shorted | 133.08 K | ||||
| EBITDA | (2.44 M) | ||||
| Net Income | (2.54 K) | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | (2.27) X | ||||
| Cash Flow From Operations | (1.52 K) | ||||
| Beta | -0.46 | ||||
| Total Asset | 8.56 M | ||||
| Retained Earnings | (14.2 M) | ||||
| Working Capital | 5.91 M | ||||
| Net Asset | 8.56 M |
About CERo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CERo Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CERo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CERo Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for CERo Stock Analysis
When running CERo Therapeutics' price analysis, check to measure CERo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CERo Therapeutics is operating at the current time. Most of CERo Therapeutics' value examination focuses on studying past and present price action to predict the probability of CERo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CERo Therapeutics' price. Additionally, you may evaluate how the addition of CERo Therapeutics to your portfolios can decrease your overall portfolio volatility.